GENOCEA BIOSCIENCES INC

As of March 31, 2022, GENOCEA BIOSCIENCES INC carries a market capitalization of 73.42M, placing it among publicly traded companies globally. Its enterprise value stands at 68.77M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

GENOCEA BIOSCIENCES INC's next confirmed earnings release is scheduled for October 29, 2026.

As of March 31, 2022, GENOCEA BIOSCIENCES INC has 58.73M shares outstanding.

These figures are as of March 31, 2022. The price-to-sales ratio is 45.67, and the price-to-book ratio stands at 5.93.

These figures are as of March 31, 2022. The EV/Sales ratio of 35.98 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 68.77M versus a market cap of 73.42M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2022, GENOCEA BIOSCIENCES INC maintains a current ratio of 1.35, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 125.03, indicating elevated leverage, while an interest coverage ratio of -50.20 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2022, GENOCEA BIOSCIENCES INC posted a negative return on equity (ROE) of -525.78, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -60.61, reflecting losses generated across the asset base. The company generates approximately 26,178.08 in revenue per employee across its workforce of 73.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended March 31, 2022, GENOCEA BIOSCIENCES INC generated 1.91M in revenue and converted that into -37.19M in net income, yielding earnings per share of -0.53. EBITDA reached -53.87M, while operating income came in at -55.44M.

As of March 31, 2022, GENOCEA BIOSCIENCES INC holds 20.14M in cash and equivalents against 15.49M in total debt, resulting in a net debt position of -12.49M. Total book value stands at 12.39M, with working capital of 6.38M providing operational flexibility.

GENOCEA BIOSCIENCES INC produced -48.19M in operating cash flow over the twelve months ended March 31, 2022. After subtracting -3.14M in capital expenditures, free cash flow totaled -51.33M - equivalent to -0.74 per share.

These figures cover the twelve months ended March 31, 2022. The operating margin of -2,901.31 and net profit margin of -1,946.15 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2022. Free cash flow yield is negative at -58.34: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.34, meaning GENOCEA BIOSCIENCES INC raised more capital through share issuance and new debt than it returned via dividends and buybacks.

GENOCEA BIOSCIENCES INC's most recent stock split took place on May 22, 2019 with a 8:1 split ratio.

As of March 31, 2022, GENOCEA BIOSCIENCES INC has an Altman Z-Score of -18.10, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.